Grifols SA
1GRF
Company Profile
Business description
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
Contact
Avinguda de la Generalitat, 152
Parc de Negocis Can Sant Joan
Sant Cugat del Valles
Barcelona08174
ESPT: +34 935712200
E: investors@grifols.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
23,554
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,704.40 | 180.10 | 2.39% |
| CAC 40 | 7,166.52 | 239.40 | 3.46% |
| DAX 40 | 20,370.40 | 580.78 | 2.93% |
| Dow JONES (US) | 37,965.60 | 2,580.33 | -6.36% |
| FTSE 100 | 7,966.43 | 264.35 | 3.43% |
| HKSE | 20,127.68 | 299.38 | 1.51% |
| NASDAQ | 15,603.26 | 947.34 | -5.72% |
| Nikkei 225 | 33,012.58 | 1,876.00 | 6.03% |
| NZX 50 Index | 11,891.44 | 115.56 | 0.98% |
| S&P 500 | 5,062.25 | 0.00 | 0.00% |
| S&P/ASX 200 | 7,510.00 | 166.70 | 2.27% |
| SSE Composite Index | 3,145.55 | 48.97 | 1.58% |